Quest Diagnostics Incorporated
Bear Case (25th pct.)
-44.0% vs price
Base Case (Median)
-16.1% vs price
Bull Case (75th pct.)
-8.8% vs price
◇ = Current price | |Bear |Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $42.25 | -82.1% | High (40%) |
| PE Comparable | $209.64 | -11.0% | Medium (25%) |
| Growth Trajectory DCF | $249.24 | 5.8% | Medium (20%) |
| Graham Number | $117.01 | -50.3% | Medium (40%) |
| EV/EBITDA | $197.66 | -16.1% | Medium (20%) |
| EV/FCF | $219.82 | -6.7% | Medium (20%) |
| Earnings Power Value | $146.73 | -37.7% | Medium (50%) |
Based on 7 out of 8 methods, DGX appears overvalued at the current price of $235.52. The base case fair value of $197.66 implies 16.1% downside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.